LOM urges buy on weakness in Theratechnologies
February 25, 2010 by leonardzehr · Leave a Comment
Theratechnologies (TSX:TH) has released new dates for the final FDA review and decision on approval of its drug tesamorelin, which should clear uncertainty surrounding the stock, Loewen, Ondaatje, McCutcheon says in a new report. “Should downward pressure occur in reaction to the delay, we believe this would present investors with a buying opportunity,” writes analyst [...]
Listen to BioTuesdays 
